AST(SGOT)/ALT(SGPT 0 18 0 18 B-clinical_variable
) 18 19 18 19 I-clinical_variable
≤2.5 20 24 20 24 O
× 25 26 25 26 I-upper_bound
institutional 27 40 27 40 I-upper_bound
upper 41 46 41 46 I-upper_bound
limit 47 52 47 52 I-upper_bound
of 53 55 53 55 I-upper_bound
normal 56 62 56 62 I-upper_bound

Active 0 6 63 69 O
autoimmune 7 17 70 80 B-chronic_disease
disease 18 25 81 88 I-chronic_disease
that 26 30 89 93 O
might 31 36 94 99 O
deteriorate 37 48 100 111 O
when 49 53 112 116 O
receiving 54 63 117 126 O
an 64 66 127 129 O
immunostimulatory 67 84 130 147 O
agent 85 90 148 153 O

Active 0 6 154 160 B-chronic_disease
infection 7 16 161 170 I-chronic_disease
requiring 17 26 171 180 O
systemic 27 35 181 189 B-treatment
therapy 36 43 190 197 I-treatment

Age 0 3 198 201 B-age
of 4 6 202 204 O
18 7 9 205 207 B-lower_bound
or 10 12 208 210 O
greater 13 20 211 218 O
years 21 26 219 224 O

All 0 3 225 228 O
other 4 9 229 234 O
significant 10 21 235 246 O
diseases 22 30 247 255 O
( 31 32 256 257 O
for 32 35 257 260 O
example 36 43 261 268 O
, 43 44 268 269 O
inflammatory 45 57 270 282 B-chronic_disease
bowel 58 63 283 288 I-chronic_disease
disease 64 71 289 296 I-chronic_disease
, 71 72 296 297 O
uncontrolled 73 85 298 310 B-chronic_disease
asthma 86 92 311 317 I-chronic_disease
) 92 93 317 318 O
, 93 94 318 319 O
which 95 100 320 325 O
, 100 101 325 326 O
in 102 104 327 329 O
the 105 108 330 333 O
opinion 109 116 334 341 O
of 117 119 342 344 O
the 120 123 345 348 O
Investigator 124 136 349 361 O
, 136 137 361 362 O
might 138 143 363 368 O
impair 144 150 369 375 O
the 151 154 376 379 O
subject 155 162 380 387 O
's 162 164 387 389 O
tolerance 165 174 390 399 O
of 175 177 400 402 O
trial 178 183 403 408 O
treatment 184 193 409 418 O

All 0 3 419 422 O
patients 4 12 423 431 O
must 13 17 432 436 O
have 18 22 437 441 O
measurable 23 33 442 452 O
disease 34 41 453 460 O
as 42 44 461 463 O
defined 45 52 464 471 O
by 53 55 472 474 O
RECIST 56 62 475 481 O
1.1 63 66 482 485 O
. 66 67 485 486 O
Measurable 68 78 487 497 O
disease 79 86 498 505 O
is 87 89 506 508 O
defined 90 97 509 516 O
as 98 100 517 519 O
at 101 103 520 522 O
least 104 109 523 528 O
one 110 113 529 532 B-lower_bound
lesion 114 120 533 539 O
that 121 125 540 544 O
can 126 129 545 548 O
be 130 132 549 551 O
accurately 133 143 552 562 O
measured 144 152 563 571 O
in 153 155 572 574 O
at 156 158 575 577 O
least 159 164 578 583 O
one 165 168 584 587 O
dimension 169 178 588 597 O
( 179 180 598 599 O
longest 180 187 599 606 O
diameter 188 196 607 615 O
to 197 199 616 618 O
be 200 202 619 621 O
recorded 203 211 622 630 O
) 211 212 630 631 O

Any 0 3 632 635 O
platinum 4 12 636 644 O
based 13 18 645 650 O
chemotherapy 19 31 651 663 B-treatment
( 32 33 664 665 O
single 33 39 665 671 O
agent 40 45 672 677 O
platinum 46 54 678 686 O
or 55 57 687 689 O
any 58 61 690 693 O
platinum 62 70 694 702 O
doublet 71 78 703 710 O
) 78 79 710 711 O
administered 80 92 712 724 O
in 93 95 725 727 O
conjunction 96 107 728 739 O
with 108 112 740 744 O
primary 113 120 745 752 O
radiation 121 130 753 762 O
as 131 133 763 765 O
a 134 135 766 767 O
radio 136 141 768 773 O
- 141 142 773 774 O
sensitizer 142 152 774 784 O
WILL 153 157 785 789 O
be 158 160 790 792 O
counted 161 168 793 800 O
as 169 171 801 803 O
a 172 173 804 805 O
systemic 174 182 806 814 B-treatment
chemotherapy 183 195 815 827 I-treatment
regimen 196 203 828 835 O

Availability 0 12 836 848 O
of 13 15 849 851 O
a 16 17 852 853 O
formalin 18 26 854 862 B-clinical_variable
fixed 27 32 863 868 I-clinical_variable
paraffin 33 41 869 877 I-clinical_variable
embedded 42 50 878 886 I-clinical_variable
( 51 52 887 888 I-clinical_variable
FFPE 52 56 888 892 I-clinical_variable
) 56 57 892 893 I-clinical_variable
block 58 63 894 899 O
of 64 66 900 902 O
cancer 67 73 903 909 B-cancer
tissue 74 80 910 916 O
from 81 85 917 921 O
the 86 89 922 925 O
original 90 98 926 934 O
surgery 99 106 935 942 B-treatment
or 107 109 943 945 O
biopsy 110 116 946 952 B-treatment
or 117 119 953 955 O
from 120 124 956 960 O
a 125 126 961 962 O
biopsy 127 133 963 969 O
of 134 136 970 972 O
recurrent 137 146 973 982 O
disease 147 154 983 990 O

Because 0 7 991 998 O
insufficient 8 20 999 1011 O
dosing 21 27 1012 1018 O
or 28 30 1019 1021 O
adverse 31 38 1022 1029 O
event 39 44 1030 1035 O
data 45 49 1036 1040 O
are 50 53 1041 1044 O
currently 54 63 1045 1054 O
available 64 73 1055 1064 O
on 74 76 1065 1067 O
the 77 80 1068 1071 O
use 81 84 1072 1075 O
of 85 87 1076 1078 O
Avelumab 88 96 1079 1087 B-treatment
in 97 99 1088 1090 O
participants 100 112 1091 1103 O
< 113 114 1104 1105 O
18 115 117 1106 1108 B-upper_bound
years 118 123 1109 1114 I-upper_bound
of 124 126 1115 1117 O
age 127 130 1118 1121 B-age

CLCR={[(140 0 11 1122 1133 B-clinical_variable
- 11 12 1133 1134 O
age 12 15 1134 1137 B-age
) 15 16 1137 1138 O
× 17 18 1139 1140 O
weight)]/(72 19 31 1141 1153 O
x 32 33 1154 1155 O
SCR 34 37 1156 1159 B-clinical_variable
) 37 38 1159 1160 O
} 38 39 1160 1161 O
× 40 41 1162 1163 O
0.85 42 46 1164 1168 O
where 47 52 1169 1174 O
CLCR 53 57 1175 1179 B-clinical_variable
( 58 59 1180 1181 I-clinical_variable
creatinine 59 69 1181 1191 I-clinical_variable
clearance 70 79 1192 1201 I-clinical_variable
) 79 80 1201 1202 I-clinical_variable
is 81 83 1203 1205 O
measured 84 92 1206 1214 O
in 93 95 1215 1217 O
mL 96 98 1218 1220 O
/ 98 99 1220 1221 O
min 99 102 1221 1224 O
, 102 103 1224 1225 O
age 104 107 1226 1229 O
is 108 110 1230 1232 O
expressed 111 120 1233 1242 O
in 121 123 1243 1245 O
years 124 129 1246 1251 O
, 129 130 1251 1252 O
weight 131 137 1253 1259 O
in 138 140 1260 1262 O
kilograms 141 150 1263 1272 O
( 151 152 1273 1274 O
kg 152 154 1274 1276 O
) 154 155 1276 1277 O
, 155 156 1277 1278 O
and 157 160 1279 1282 O
SCR 161 164 1283 1286 B-clinical_variable
( 165 166 1287 1288 I-clinical_variable
serum 166 171 1288 1293 I-clinical_variable
creatinine 172 182 1294 1304 I-clinical_variable
) 182 183 1304 1305 I-clinical_variable
in 184 186 1306 1308 O
mg 187 189 1309 1311 O
/ 189 190 1311 1312 O
dL 190 192 1312 1314 O

Clinically 0 10 1315 1325 O
significant 11 22 1326 1337 O
( 23 24 1338 1339 O
i.e. 24 28 1339 1343 O
, 28 29 1343 1344 O
active 30 36 1345 1351 O
) 36 37 1351 1352 O
cardiovascular 38 52 1353 1367 B-chronic_disease
disease 53 60 1368 1375 I-chronic_disease
: 60 61 1375 1376 O
cerebral 62 70 1377 1385 B-chronic_disease
vascular 71 79 1386 1394 I-chronic_disease
accident 80 88 1395 1403 I-chronic_disease
/ 88 89 1403 1404 I-chronic_disease
stroke 89 95 1404 1410 I-chronic_disease
( 96 97 1411 1412 O
< 97 98 1412 1413 O
6 99 100 1414 1415 B-upper_bound
months 101 107 1416 1422 I-upper_bound
prior 108 113 1423 1428 I-upper_bound
to 114 116 1429 1431 O
enrollment 117 127 1432 1442 O
) 127 128 1442 1443 O
, 128 129 1443 1444 O
myocardial 130 140 1445 1455 B-chronic_disease
infarction 141 151 1456 1466 I-chronic_disease
( 152 153 1467 1468 O
< 153 154 1468 1469 O
6 155 156 1470 1471 O
months 157 163 1472 1478 O
prior 164 169 1479 1484 O
to 170 172 1485 1487 O
enrollment 173 183 1488 1498 O
) 183 184 1498 1499 O
, 184 185 1499 1500 O
unstable 186 194 1501 1509 B-chronic_disease
angina 195 201 1510 1516 I-chronic_disease
, 201 202 1516 1517 O
congestive 203 213 1518 1528 B-chronic_disease
heart 214 219 1529 1534 I-chronic_disease
failure 220 227 1535 1542 I-chronic_disease
( 228 229 1543 1544 O
≥ 229 230 1544 1545 O
New 231 234 1546 1549 O
York 235 239 1550 1554 O
Heart 240 245 1555 1560 O
Association 246 257 1561 1572 O
Classification 258 272 1573 1587 O
Class 273 278 1588 1593 O
II 279 281 1594 1596 O
) 281 282 1596 1597 O
, 282 283 1597 1598 O
or 284 286 1599 1601 O
serious 287 294 1602 1609 O
cardiac 295 302 1610 1617 B-chronic_disease
arrhythmia 303 313 1618 1628 I-chronic_disease
requiring 314 323 1629 1638 O
medication 324 334 1639 1649 O

Current 0 7 1650 1657 O
or 8 10 1658 1660 O
prior 11 16 1661 1666 B-treatment
use 17 20 1667 1670 I-treatment
of 21 23 1671 1673 I-treatment
immunosuppressive 24 41 1674 1691 I-treatment
medication 42 52 1692 1702 I-treatment
within 53 59 1703 1709 O
7 60 61 1710 1711 B-upper_bound
days 62 66 1712 1716 I-upper_bound
prior 67 72 1717 1722 I-upper_bound
to 73 75 1723 1725 O
enrollment 76 86 1726 1736 O

Each 0 4 1737 1741 O
lesion 5 11 1742 1748 B-clinical_variable
must 12 16 1749 1753 O
be 17 19 1754 1756 O
> 20 21 1757 1758 O
= 21 22 1758 1759 O
10 23 25 1760 1762 B-lower_bound
mm 26 28 1763 1765 I-lower_bound
when 29 33 1766 1770 O
measured 34 42 1771 1779 O
by 43 45 1780 1782 O
CT 46 48 1783 1785 O
, 48 49 1785 1786 O
MRI 50 53 1787 1790 O
or 54 56 1791 1793 O
caliper 57 64 1794 1801 O
measurement 65 76 1802 1813 O
by 77 79 1814 1816 O
clinical 80 88 1817 1825 O
exam 89 93 1826 1830 O
; 93 94 1830 1831 O
or 95 97 1832 1834 O
> 98 99 1835 1836 O
= 99 100 1836 1837 O
20 101 103 1838 1840 B-lower_bound
mm 104 106 1841 1843 I-lower_bound
when 107 111 1844 1848 O
measured 112 120 1849 1857 O
by 121 123 1858 1860 O
chest 124 129 1861 1866 O
x 130 131 1867 1868 O
- 131 132 1868 1869 O
ray 132 135 1869 1872 O

Endometrial 0 11 1873 1884 B-cancer
cancer 12 18 1885 1891 I-cancer
is 19 21 1892 1894 O
very 22 26 1895 1899 O
rare 27 31 1900 1904 O
in 32 34 1905 1907 O
the 35 38 1908 1911 O
pediatric 39 48 1912 1921 O
population 49 59 1922 1932 O

Endometrial 0 11 1933 1944 B-cancer
cancers 12 19 1945 1952 I-cancer
that 20 24 1953 1957 O
are 25 28 1958 1961 O
MSS 29 32 1962 1965 O
as 33 35 1966 1968 O
determined 36 46 1969 1979 O
by 47 49 1980 1982 O
normal 50 56 1983 1989 O
immunohistochemical 57 76 1990 2009 O
nuclear 77 84 2010 2017 O
expression 85 95 2018 2028 O
of 96 98 2029 2031 O
all 99 102 2032 2035 O
the 103 106 2036 2039 O
mismatch 107 115 2040 2048 O
repair 116 122 2049 2055 O
genes 123 128 2056 2061 O
MSH2 129 133 2062 2066 O
, 133 134 2066 2067 O
MSH6 135 139 2068 2072 O
, 139 140 2072 2073 O
MLH1 141 145 2074 2078 O
and 146 149 2079 2082 O
PMS2 150 154 2083 2087 O

Females 0 7 2088 2095 B-gender
of 8 10 2096 2098 O
childbearing 11 23 2099 2111 O
potential 24 33 2112 2121 O
are 34 37 2122 2125 O
defined 38 45 2126 2133 O
as 46 48 2134 2136 O
those 49 54 2137 2142 O
who 55 58 2143 2146 O
are 59 62 2147 2150 O
not 63 66 2151 2154 O
surgically 67 77 2155 2165 O
sterile 78 85 2166 2173 O
( 86 87 2174 2175 O
i.e. 87 91 2175 2179 O
, 91 92 2179 2180 O
bilateral 93 102 2181 2190 B-treatment
tubal 103 108 2191 2196 I-treatment
ligation 109 117 2197 2205 I-treatment
, 117 118 2205 2206 O
bilateral 119 128 2207 2216 B-treatment
oophorectomy 129 141 2217 2229 I-treatment
, 141 142 2229 2230 O
or 143 145 2231 2233 O
complete 146 154 2234 2242 B-treatment
hysterectomy 155 167 2243 2255 I-treatment
) 167 168 2255 2256 O
or 169 171 2257 2259 O
post 172 176 2260 2264 O
- 176 177 2264 2265 O
menopausal 177 187 2265 2275 O
( 188 189 2276 2277 O
defined 189 196 2277 2284 O
as 197 199 2285 2287 O
≥ 200 201 2288 2289 O
12 202 204 2290 2292 B-lower_bound
months 205 211 2293 2299 I-lower_bound
with 212 216 2300 2304 O
no 217 219 2305 2307 O
menses 220 226 2308 2314 O
without 227 234 2315 2322 O
an 235 237 2323 2325 O
alternative 238 249 2326 2337 O
medical 250 257 2338 2345 O
cause 258 263 2346 2351 O
) 263 264 2351 2352 O

For 0 3 2353 2356 O
this 4 8 2357 2361 O
reason 9 15 2362 2368 O
and 16 19 2369 2372 O
because 20 27 2373 2380 O
some 28 32 2381 2385 O
immunomodulatory 33 49 2386 2402 B-treatment
agents 50 56 2403 2409 I-treatment
are 57 60 2410 2413 O
known 61 66 2414 2419 O
to 67 69 2420 2422 O
be 70 72 2423 2425 O
teratogenic 73 84 2426 2437 B-treatment
, 84 85 2437 2438 O
women 86 91 2439 2444 B-gender
of 92 94 2445 2447 O
child 95 100 2448 2453 O
- 100 101 2453 2454 O
bearing 101 108 2454 2461 O
potential 109 118 2462 2471 O
must 119 123 2472 2476 O
agree 124 129 2477 2482 B-contraception_consent
to 130 132 2483 2485 I-contraception_consent
use 133 136 2486 2489 I-contraception_consent
adequate 137 145 2490 2498 I-contraception_consent
contraception 146 159 2499 2512 I-contraception_consent
( 160 161 2513 2514 O
hormonal 161 169 2514 2522 O
or 170 172 2523 2525 O
barrier 173 180 2526 2533 O
method 181 187 2534 2540 O
of 188 190 2541 2543 O
birth 191 196 2544 2549 O
control 197 204 2550 2557 O
; 204 205 2557 2558 O
abstinence 206 216 2559 2569 O
) 216 217 2569 2570 O
prior 218 223 2571 2576 O
to 224 226 2577 2579 O
study 227 232 2580 2585 O
entry 233 238 2586 2591 O
and 239 242 2592 2595 O
for 243 246 2596 2599 O
the 247 250 2600 2603 O
duration 251 259 2604 2612 O
of 260 262 2613 2615 O
study 263 268 2616 2621 O
participation 269 282 2622 2635 O

Grade 0 5 2636 2641 B-chronic_disease
2 6 7 2642 2643 I-chronic_disease
sensory 8 15 2644 2651 I-chronic_disease
neuropathy 16 26 2652 2662 I-chronic_disease

History 0 7 2663 2670 O
of 8 10 2671 2673 O
allergic 11 19 2674 2682 O
reactions 20 29 2683 2692 O
attributed 30 40 2693 2703 O
to 41 43 2704 2706 O
avelumab 44 52 2707 2715 B-allergy_name
or 53 55 2716 2718 O
any 56 59 2719 2722 O
component 60 69 2723 2732 O
in 70 72 2733 2735 O
its 73 76 2736 2739 O
formulations 77 89 2740 2752 O
, 89 90 2752 2753 O
or 91 93 2754 2756 O
compounds 94 103 2757 2766 O
of 104 106 2767 2769 O
similar 107 114 2770 2777 O
chemical 115 123 2778 2786 O
or 124 126 2787 2789 O
biologic 127 135 2790 2798 O
composition 136 147 2799 2810 O
to 148 150 2811 2813 O
avelumab 151 159 2814 2822 O

Individuals 0 11 2823 2834 O
with 12 16 2835 2839 O
a 17 18 2840 2841 O
history 19 26 2842 2849 O
of 27 29 2850 2852 O
a 30 31 2853 2854 O
different 32 41 2855 2864 O
malignancy 42 52 2865 2875 B-cancer

Intranasal 0 10 2876 2886 B-treatment
, 10 11 2886 2887 O
inhaled 12 19 2888 2895 B-treatment
, 19 20 2895 2896 O
topical 21 28 2897 2904 B-treatment
steroids 29 37 2905 2913 I-treatment
, 37 38 2913 2914 O
or 39 41 2915 2917 O
local 42 47 2918 2923 B-treatment
steroid 48 55 2924 2931 I-treatment
injections 56 66 2932 2942 I-treatment
( 67 68 2943 2944 O
eg 68 70 2944 2946 O
, 70 71 2946 2947 O
intra 72 77 2948 2953 B-treatment
- 77 78 2953 2954 I-treatment
articular 78 87 2954 2963 I-treatment
injection 88 97 2964 2973 I-treatment
) 97 98 2973 2974 O

Known 0 5 2975 2980 O
human 6 11 2981 2986 B-chronic_disease
immunodeficiency 12 28 2987 3003 I-chronic_disease
virus 29 34 3004 3009 I-chronic_disease
( 35 36 3010 3011 I-chronic_disease
HIV 36 39 3011 3014 I-chronic_disease
) 39 40 3014 3015 I-chronic_disease
or 41 43 3016 3018 O
acquired 44 52 3019 3027 B-chronic_disease
immunodeficiency 53 69 3028 3044 I-chronic_disease
syndrome 70 78 3045 3053 I-chronic_disease
( 79 80 3054 3055 I-chronic_disease
AIDS 80 84 3055 3059 I-chronic_disease
) 84 85 3059 3060 I-chronic_disease
related 86 93 3061 3068 I-chronic_disease
illness 94 101 3069 3076 I-chronic_disease
, 101 102 3076 3077 O
which 103 108 3078 3083 O
may 109 112 3084 3087 O
compromise 113 123 3088 3098 O
the 124 127 3099 3102 O
efficacy 128 136 3103 3111 O
of 137 139 3112 3114 O
immunostimulatory 140 157 3115 3132 B-treatment
therapy 158 165 3133 3140 I-treatment

Lymph 0 5 3141 3146 B-clinical_variable
nodes 6 11 3147 3152 I-clinical_variable
must 12 16 3153 3157 O
be 17 19 3158 3160 O
> 20 21 3161 3162 O
15 22 24 3163 3165 B-lower_bound
mm 25 27 3166 3168 I-lower_bound
in 28 30 3169 3171 O
short 31 36 3172 3177 O
axis 37 41 3178 3182 O
when 42 46 3183 3187 O
measured 47 55 3188 3196 O
by 56 58 3197 3199 O
CT 59 61 3200 3202 O
or 62 64 3203 3205 O
MRI 65 68 3206 3209 O

POLE 0 4 3210 3214 O
- 4 5 3214 3215 O
mutated 5 12 3215 3222 O
, 12 13 3222 3223 O
i.e. 14 18 3224 3228 O
endometrial 19 30 3229 3240 B-cancer
cancers 31 38 3241 3248 I-cancer
known 39 44 3249 3254 O
to 45 47 3255 3257 O
harbor 48 54 3258 3264 O
mutations 55 64 3265 3274 O
in 65 67 3275 3277 O
the 68 71 3278 3281 O
exonuclease 72 83 3282 3293 O
domain 84 90 3294 3300 O
( 91 92 3301 3302 O
amino 92 97 3302 3307 O
acid 98 102 3308 3312 O
residues 103 111 3313 3321 O
268 112 115 3322 3325 O
- 115 116 3325 3326 O
471 116 119 3326 3329 O
) 119 120 3329 3330 O
of 121 123 3331 3333 O
polymerase 124 134 3334 3344 O
e 135 136 3345 3346 O
( 137 138 3347 3348 O
POLE 138 142 3348 3352 O
) 142 143 3352 3353 O
as 144 146 3354 3356 O
determined 147 157 3357 3367 O
by 158 160 3368 3370 O
targeted 161 169 3371 3379 O
sequencing 170 180 3380 3390 O
or 181 183 3391 3393 O
other 184 189 3394 3399 O
next 190 194 3400 3404 O
generation 195 205 3405 3415 O
sequencing 206 216 3416 3426 O
assay 217 222 3427 3432 O

Participant 0 11 3433 3444 O
must 12 16 3445 3449 B-pregnancy
not 17 20 3450 3453 I-pregnancy
be 21 23 3454 3456 I-pregnancy
pregnant 24 32 3457 3465 I-pregnancy
or 33 35 3466 3468 O
breastfeeding 36 49 3469 3482 O
given 50 55 3483 3488 O
that 56 60 3489 3493 O
avelumab 61 69 3494 3502 B-treatment
is 70 72 3503 3505 O
an 73 75 3506 3508 O
agent 76 81 3509 3514 O
with 82 86 3515 3519 O
unknown 87 94 3520 3527 O
effects 95 102 3528 3535 O
in 103 105 3536 3538 O
pregnancy 106 115 3539 3548 B-pregnancy
and 116 119 3549 3552 O
breastfeeding 120 133 3553 3566 O
and 134 137 3567 3570 O
the 138 141 3571 3574 O
potential 142 151 3575 3584 O
for 152 155 3585 3588 O
teratogenesis 156 169 3589 3602 O

Participants 0 12 3603 3615 O
with 13 17 3616 3620 O
a 18 19 3621 3622 O
history 20 27 3623 3630 O
of 28 30 3631 3633 O
treatment 31 40 3634 3643 B-treatment
with 41 45 3644 3648 I-treatment
an 46 48 3649 3651 I-treatment
anti 49 53 3652 3656 I-treatment
- 53 54 3656 3657 I-treatment
PD-1 54 58 3657 3661 I-treatment
, 58 59 3661 3662 O
anti 60 64 3663 3667 B-treatment
- 64 65 3667 3668 I-treatment
PD 65 67 3668 3670 I-treatment
- 67 68 3670 3671 I-treatment
L1 68 70 3671 3673 I-treatment
, 70 71 3673 3674 O
anti 72 76 3675 3679 B-treatment
- 76 77 3679 3680 I-treatment
CTLA-4 77 83 3680 3686 I-treatment
or 84 86 3687 3689 O
other 87 92 3690 3695 O
investigational 93 108 3696 3711 O
agents 109 115 3712 3718 O
that 116 120 3719 3723 O
target 121 127 3724 3730 O
immune 128 134 3731 3737 O
checkpoint 135 145 3738 3748 O
inhibitors 146 156 3749 3759 O

Participants 0 12 3760 3772 O
with 13 17 3773 3777 O
known 18 23 3778 3783 O
brain 24 29 3784 3789 B-cancer
metastases 30 40 3790 3800 I-cancer
should 41 47 3801 3807 O
be 48 50 3808 3810 O
excluded 51 59 3811 3819 O
from 60 64 3820 3824 O
this 65 69 3825 3829 O
clinical 70 78 3830 3838 O
trial 79 84 3839 3844 O
because 85 92 3845 3852 O
of 93 95 3853 3855 O
their 96 101 3856 3861 O
poor 102 106 3862 3866 O
prognosis 107 116 3867 3876 O
and 117 120 3877 3880 O
because 121 128 3881 3888 O
they 129 133 3889 3893 O
often 134 139 3894 3899 O
develop 140 147 3900 3907 O
progressive 148 159 3908 3919 O
neurologic 160 170 3920 3930 B-chronic_disease
dysfunction 171 182 3931 3942 I-chronic_disease
that 183 187 3943 3947 O
would 188 193 3948 3953 O
confound 194 202 3954 3962 O
the 203 206 3963 3966 O
evaluation 207 217 3967 3977 O
of 218 220 3978 3980 O
neurologic 221 231 3981 3991 O
and 232 235 3992 3995 O
other 236 241 3996 4001 O
adverse 242 249 4002 4009 O
events 250 256 4010 4016 O

Patients 0 8 4017 4025 O
must 9 13 4026 4030 O
NOT 14 17 4031 4034 O
have 18 22 4035 4039 O
received 23 31 4040 4048 O
any 32 35 4049 4052 O
prior 36 41 4053 4058 O
PARP 42 46 4059 4063 O
inhibitor 47 56 4064 4073 B-treatment
therapy 57 64 4074 4081 I-treatment

Patients 0 8 4082 4090 O
with 9 13 4091 4095 O
diabetes 14 22 4096 4104 B-chronic_disease
type 23 27 4105 4109 I-chronic_disease
I 28 29 4110 4111 I-chronic_disease
, 29 30 4111 4112 O
vitiligo 31 39 4113 4121 B-chronic_disease
, 39 40 4121 4122 O
psoriasis 41 50 4123 4132 B-chronic_disease
, 50 51 4132 4133 O
hypo- 52 57 4134 4139 B-chronic_disease
or 58 60 4140 4142 I-chronic_disease
hyperthyroid 61 73 4143 4155 I-chronic_disease
disease 74 81 4156 4163 I-chronic_disease
not 82 85 4164 4167 O
requiring 86 95 4168 4177 O
immunosuppressive 96 113 4178 4195 B-treatment
treatment 114 123 4196 4205 I-treatment

Patients 0 8 4206 4214 O
with 9 13 4215 4219 O
moderate 14 22 4220 4228 O
renal 23 28 4229 4234 B-chronic_disease
impairment 29 39 4235 4245 I-chronic_disease
( 40 41 4246 4247 O
defined 41 48 4247 4254 O
as 49 51 4255 4257 O
an 52 54 4258 4260 O
estimated 55 64 4261 4270 O
creatinine 65 75 4271 4281 B-clinical_variable
clearance 76 85 4282 4291 I-clinical_variable
of 86 88 4292 4294 O
30 89 91 4295 4297 B-lower_bound
- 91 92 4297 4298 O
59 92 94 4298 4300 B-upper_bound
mL 95 97 4301 4303 I-upper_bound
/ 97 98 4303 4304 I-upper_bound
min 98 101 4304 4307 I-upper_bound
) 101 102 4307 4308 O
will 103 107 4309 4313 O
receive 108 115 4314 4321 O
a 116 117 4322 4323 O
reduced 118 125 4324 4331 O
starting 126 134 4332 4340 O
dose 135 139 4341 4345 O
of 140 142 4346 4348 O
Talazoparib 143 154 4349 4360 B-treatment
at 155 157 4361 4363 O
0.75 158 162 4364 4368 O
mg 163 165 4369 4371 O
PO 166 168 4372 4374 O
QD 169 171 4375 4377 O

Persisting 0 10 4378 4388 B-clinical_variable
Grade 11 16 4389 4394 I-clinical_variable
> 17 18 4395 4396 O
= 18 19 4396 4397 O
2 19 20 4397 4398 B-lower_bound
toxicity 21 29 4399 4407 O
related 30 37 4408 4415 O
to 38 40 4416 4418 O
prior 41 46 4419 4424 B-treatment
therapy 47 54 4425 4432 I-treatment

Prior 0 5 4433 4438 B-treatment
hormonal 6 14 4439 4447 I-treatment
therapy 15 22 4448 4455 I-treatment

Prior 0 5 4456 4461 B-treatment
organ 6 11 4462 4467 I-treatment
transplantation 12 27 4468 4483 I-treatment
including 28 37 4484 4493 O
allogeneic 38 48 4494 4504 B-treatment
stem 49 53 4505 4509 I-treatment
- 53 54 4509 4510 I-treatment
cell 54 58 4510 4514 I-treatment
transplantation 59 74 4515 4530 I-treatment

Severe 0 6 4531 4537 O
gastrointestinal 7 23 4538 4554 B-chronic_disease
conditions 24 34 4555 4565 O
such 35 39 4566 4570 O
as 40 42 4571 4573 O
clinical 43 51 4574 4582 O
or 52 54 4583 4585 O
radiological 55 67 4586 4598 O
evidence 68 76 4599 4607 O
of 77 79 4608 4610 O
bowel 80 85 4611 4616 B-chronic_disease
obstruction 86 97 4617 4628 I-chronic_disease
within 98 104 4629 4635 O
4 105 106 4636 4637 B-upper_bound
weeks 107 112 4638 4643 I-upper_bound
prior 113 118 4644 4649 I-upper_bound
to 119 121 4650 4652 O
study 122 127 4653 4658 O
entry 128 133 4659 4664 O
, 133 134 4664 4665 O
uncontrolled 135 147 4666 4678 O
diarrhea 148 156 4679 4687 B-chronic_disease
in 157 159 4688 4690 O
the 160 163 4691 4694 O
last 164 168 4695 4699 B-upper_bound
4 169 170 4700 4701 I-upper_bound
weeks 171 176 4702 4707 I-upper_bound
prior 177 182 4708 4713 I-upper_bound
to 183 185 4714 4716 O
enrollment 186 196 4717 4727 O
, 196 197 4727 4728 O
or 198 200 4729 4731 O
history 201 208 4732 4739 O
of 209 211 4740 4742 O
inflammatory 212 224 4743 4755 B-chronic_disease
bowel 225 230 4756 4761 I-chronic_disease
disease 231 238 4762 4769 I-chronic_disease

Should 0 6 4770 4776 O
a 7 8 4777 4778 O
woman 9 14 4779 4784 B-gender
become 15 21 4785 4791 O
pregnant 22 30 4792 4800 B-pregnancy
or 31 33 4801 4803 O
suspect 34 41 4804 4811 B-pregnancy
she 42 45 4812 4815 I-pregnancy
is 46 48 4816 4818 I-pregnancy
pregnant 49 57 4819 4827 I-pregnancy
while 58 63 4828 4833 O
she 64 67 4834 4837 O
or 68 70 4838 4840 O
her 71 74 4841 4844 O
partner 75 82 4845 4852 O
is 83 85 4853 4855 O
participating 86 99 4856 4869 O
in 100 102 4870 4872 O
this 103 107 4873 4877 O
study 108 113 4878 4883 O
, 113 114 4883 4884 O
she 115 118 4885 4888 O
should 119 125 4889 4895 O
inform 126 132 4896 4902 O
her 133 136 4903 4906 O
treating 137 145 4907 4915 O
physician 146 155 4916 4925 O
immediately 156 167 4926 4937 O

Subjects 0 8 4938 4946 O
requiring 9 18 4947 4956 O
hormone 19 26 4957 4964 B-treatment
replacement 27 38 4965 4976 I-treatment
with 39 43 4977 4981 I-treatment
corticosteroids 44 59 4982 4997 I-treatment
are 60 63 4998 5001 O
eligible 64 72 5002 5010 O
if 73 75 5011 5013 O
the 76 79 5014 5017 O
steroids 80 88 5018 5026 O
are 89 92 5027 5030 O
administered 93 105 5031 5043 O
only 106 110 5044 5048 O
for 111 114 5049 5052 O
the 115 118 5053 5056 O
purpose 119 126 5057 5064 O
of 127 129 5065 5067 O
hormonal 130 138 5068 5076 B-treatment
replacement 139 150 5077 5088 I-treatment
and 151 154 5089 5092 O
at 155 157 5093 5095 O
doses 158 163 5096 5101 O
≤ 164 165 5102 5103 O
10 166 168 5104 5106 B-upper_bound
mg 169 171 5107 5109 I-upper_bound
or 172 174 5110 5112 O
10 175 177 5113 5115 O
mg 178 180 5116 5118 O
equivalent 181 191 5119 5129 O
prednisone 192 202 5130 5140 B-treatment
per 203 206 5141 5144 O
day 207 210 5145 5148 O

Systemic 0 8 5149 5157 B-treatment
corticosteroids 9 24 5158 5173 I-treatment
at 25 27 5174 5176 O
physiologic 28 39 5177 5188 O
doses 40 45 5189 5194 O
not 46 49 5195 5198 O
to 50 52 5199 5201 O
exceed 53 59 5202 5208 O
10 60 62 5209 5211 B-upper_bound
mg 63 65 5212 5214 I-upper_bound
/ 65 66 5214 5215 I-upper_bound
day 66 69 5215 5218 I-upper_bound
of 70 72 5219 5221 O
prednisone 73 83 5222 5232 B-treatment
or 84 86 5233 5235 O
equivalent 87 97 5236 5246 O

The 0 3 5247 5250 O
effects 4 11 5251 5258 O
of 12 14 5259 5261 O
avelumab 15 23 5262 5270 B-treatment
on 24 26 5271 5273 O
the 27 30 5274 5277 O
developing 31 41 5278 5288 O
human 42 47 5289 5294 O
fetus 48 53 5295 5300 O
are 54 57 5301 5304 O
unknown 58 65 5305 5312 O

There 0 5 5313 5318 O
is 6 8 5319 5321 O
no 9 11 5322 5324 O
upper 12 17 5325 5330 O
limit 18 23 5331 5336 O
of 24 26 5337 5339 O
prior 27 32 5340 5345 B-treatment
therapies 33 42 5346 5355 I-treatment
but 43 46 5356 5359 O
patients 47 55 5360 5368 O
must 56 60 5369 5373 O
have 61 65 5374 5378 O
had 66 69 5379 5382 O
one 70 73 5383 5386 B-lower_bound
prior 74 79 5387 5392 B-treatment
chemotherapeutic 80 96 5393 5409 I-treatment
regimen 97 104 5410 5417 I-treatment
for 105 108 5418 5421 O
management 109 119 5422 5432 O
of 120 122 5433 5435 O
endometrial 123 134 5436 5447 B-cancer
carcinoma 135 144 5448 5457 I-cancer

This 0 4 5458 5462 O
test 5 9 5463 5467 O
is 10 12 5468 5470 O
now 13 16 5471 5474 O
done 17 21 5475 5479 O
routinely 22 31 5480 5489 O
for 32 35 5490 5493 O
every 36 41 5494 5499 O
newly 42 47 5500 5505 O
diagnosed 48 57 5506 5515 O
endometrial 58 69 5516 5527 B-cancer
cancer 70 76 5528 5534 I-cancer
patient 77 84 5535 5542 O
in 85 87 5543 5545 O
most 88 92 5546 5550 O
centers 93 100 5551 5558 O
in 101 103 5559 5561 O
the 104 107 5562 5565 O
US 108 110 5566 5568 O

Tumors 0 6 5569 5575 B-cancer
which 7 12 5576 5581 O
have 13 17 5582 5586 O
not 18 21 5587 5590 O
been 22 26 5591 5595 O
sequenced 27 36 5596 5605 O
for 37 40 5606 5609 O
POLE 41 45 5610 5614 O
mutations 46 55 5615 5624 O
( 56 57 5625 5626 O
i.e. 57 61 5626 5630 O
their 62 67 5631 5636 O
POLE 68 72 5637 5641 O
mutations 73 82 5642 5651 O
status 83 89 5652 5658 O
is 90 92 5659 5661 O
unknown 93 100 5662 5669 O
) 100 101 5669 5670 O
but 102 105 5671 5674 O
are 106 109 5675 5678 O
MSS 110 113 5679 5682 O

Uncontrolled 0 12 5683 5695 O
intercurrent 13 25 5696 5708 B-chronic_disease
illness 26 33 5709 5716 I-chronic_disease
including 34 43 5717 5726 O
, 43 44 5726 5727 O
but 45 48 5728 5731 O
not 49 52 5732 5735 O
limited 53 60 5736 5743 O
to 61 63 5744 5746 O
symptomatic 64 75 5747 5758 O
congestive 76 86 5759 5769 B-chronic_disease
heart 87 92 5770 5775 I-chronic_disease
failure 93 100 5776 5783 I-chronic_disease
, 100 101 5783 5784 O
unstable 102 110 5785 5793 B-chronic_disease
angina 111 117 5794 5800 I-chronic_disease
pectoris 118 126 5801 5809 I-chronic_disease
, 126 127 5809 5810 O
cardiac 128 135 5811 5818 B-chronic_disease
arrhythmia 136 146 5819 5829 I-chronic_disease
, 146 147 5829 5830 O
or 148 150 5831 5833 O
psychiatric 151 162 5834 5845 B-chronic_disease
illness 163 170 5846 5853 I-chronic_disease
/ 170 171 5853 5854 O
social 171 177 5854 5860 B-chronic_disease
situations 178 188 5861 5871 I-chronic_disease
that 189 193 5872 5876 O
would 194 199 5877 5882 O
limit 200 205 5883 5888 O
compliance 206 216 5889 5899 O
with 217 221 5900 5904 O
study 222 227 5905 5910 O
requirements 228 240 5911 5923 O

Vaccination 0 11 5924 5935 B-treatment
within 12 18 5936 5942 O
4 19 20 5943 5944 B-upper_bound
weeks 21 26 5945 5950 I-upper_bound
of 27 29 5951 5953 O
the 30 33 5954 5957 O
first 34 39 5958 5963 O
dose 40 44 5964 5968 O
of 45 47 5969 5971 O
avelumab 48 56 5972 5980 B-treatment
and 57 60 5981 5984 O
while 61 66 5985 5990 O
on 67 69 5991 5993 O
trial 70 75 5994 5999 O
is 76 78 6000 6002 O
prohibited 79 89 6003 6013 O
except 90 96 6014 6020 O
for 97 100 6021 6024 O
administration 101 115 6025 6039 O
of 116 118 6040 6042 O
inactivated 119 130 6043 6054 O
vaccines 131 139 6055 6063 O

absolute 0 8 6064 6072 B-clinical_variable
neutrophil 9 19 6073 6083 I-clinical_variable
count 20 25 6084 6089 I-clinical_variable
> 26 27 6090 6091 O
1,500 27 32 6091 6096 B-lower_bound
/ 32 33 6096 6097 I-lower_bound
mcL 33 36 6097 6100 I-lower_bound

creatinine 0 10 6101 6111 B-clinical_variable
clearance 11 20 6112 6121 I-clinical_variable
≥60 21 24 6122 6125 O
mL 25 27 6126 6128 I-lower_bound
/ 27 28 6128 6129 I-lower_bound
min/1.73 28 36 6129 6137 I-lower_bound
m2 37 39 6138 6140 I-lower_bound
for 40 43 6141 6144 O
participants 44 56 6145 6157 O
with 57 61 6158 6162 O
creatinine 62 72 6163 6173 O
levels 73 79 6174 6180 O
above 80 85 6181 6186 O
institutional 86 99 6187 6200 O
normal 100 106 6201 6207 O

first 0 5 6208 6213 O
cohort 6 12 6214 6220 O
( 13 14 6221 6222 O
MSI 14 17 6222 6225 O
/ 17 18 6225 6226 O
POLE 18 22 6226 6230 O
cohort 23 29 6231 6237 O
) 29 30 6237 6238 O
includes 31 39 6239 6247 O
endometrial 40 51 6248 6259 B-cancer
cancers 52 59 6260 6267 I-cancer

hemoglobin 0 10 6268 6278 B-clinical_variable
≥ 11 12 6279 6280 O
9g 13 15 6281 6283 B-lower_bound
/ 15 16 6283 6284 I-lower_bound
dL 16 18 6284 6286 I-lower_bound

patients 0 8 6287 6295 O
who 9 12 6296 6299 O
have 13 17 6300 6304 O
only 18 22 6305 6309 O
received 23 31 6310 6318 O
chemotherapy 32 44 6319 6331 B-treatment
in 45 47 6332 6334 O
the 48 51 6335 6338 O
adjuvant 52 60 6339 6347 O
setting 61 68 6348 6355 O

platelets 0 9 6356 6365 B-clinical_variable
> 10 11 6366 6367 O
100,000 11 18 6367 6374 B-lower_bound
/ 18 19 6374 6375 I-lower_bound
mcL 19 22 6375 6378 I-lower_bound

total 0 5 6379 6384 O
bilirubin 6 15 6385 6394 B-clinical_variable
within 16 22 6395 6401 O
normal 23 29 6402 6408 O
institutional 30 43 6409 6422 O
limits 44 50 6423 6429 O

